Floatz logo

Bms-936558-01

Triple Negative Breast Neoplasms

Bristol-Myers SquibbPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

447 Active assets in the Triple Negative Breast Neoplasms cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Famitinib
Fudan University
Phase 3BB

View all 50 →

Same molecule, other indications

Bms-936558-01 is also rated in:

gastroesophageal junction adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →